Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Idenix Pharmaceuticals, Inc.

http://www.idenix.com/

Latest From Idenix Pharmaceuticals, Inc.

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

United States BioPharmaceutical

Waylivra Funding Success In England & Germany

Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.

Germany United Kingdom

Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone

Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.

Deals Business Strategies

Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms

The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.

Cardiovascular Deals
See All

Company Information

  • Other Names / Subsidiaries
    • Novirio Pharmaceuticals Limited
UsernamePublicRestriction

Register